Search results for "Propensity Score"

showing 10 items of 129 documents

Carga de comorbilidad y beneficio de la revascularización en ancianos con síndrome coronario agudo

2021

Introduction and objectives: To evaluate the interaction between comorbidity burden and the benefits of in-hospital revascularization in elderly patients with non-ST-segment elevation acute coronary syndrome (NSTEACS). Methods: This retrospective study included 7211 patients aged ≥ 70 years from 11 Spanish NSTEACS registries. Six comorbidities were evaluated: diabetes, peripheral artery disease, cerebrovascular disease, chronic pulmonary disease, renal failure, and anemia. A propensity score was estimated to enable an adjusted comparison of in-hospital revascularization and conservative management. The end point was 1-year all-cause mortality. Results: In total, 1090 patients (15%) died. Th…

medicine.medical_specialtyAcute coronary syndromeAnemiamedicine.medical_treatmentEnfermedad cardiovascularAncianoComorbidity030204 cardiovascular system & hematologyCardiologíaRevascularization03 medical and health sciencesPercutaneous Coronary Intervention0302 clinical medicineDiabetes mellitusInternal medicinemedicineHumansSíndrome coronario agudoRegistriesAcute Coronary SyndromePropensity ScoreStrokeAgedRetrospective Studiesbusiness.industryRetrospective cohort studyGeneral Medicinemedicine.diseaseComorbidityTreatment OutcomeRevascularización miocárdicaPropensity score matchingCardiologybusiness
researchProduct

Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: An individual patient data meta-analysis

2021

ObjectiveThe benefit of direct-acting antivirals (DAAs) against HCV following successful treatment of hepatocellular carcinoma (HCC) remains controversial. This meta-analysis of individual patient data assessed HCC recurrence risk following DAA administration.DesignWe pooled the data of 977 consecutive patients from 21 studies of HCV-related cirrhosis and HCC, who achieved complete radiological response after surgical/locoregional treatments and received DAAs (DAA group). Recurrence or death risk was expressed as HCC recurrence or death per 100 person-years (100PY). Propensity score-matched patients from the ITA.LI.CA. cohort (n=328) served as DAA-unexposed controls (no-DAA group). Risk fac…

medicine.medical_specialtyCarcinoma HepatocellularCirrhosisAntiviral AgentsGastroenterology03 medical and health sciences0302 clinical medicineInternal medicineantiviral therapymedicineHumansPropensity Scoreantiviral therapy; hepatocellular carcinoma; meta-analysisbusiness.industryLiver NeoplasmsGastroenterologyAntiviral therapyPatient datahepatocellular carcinomamedicine.disease3. Good healthmeta-analysis030220 oncology & carcinogenesisMeta-analysisHepatocellular carcinomaRelative riskCohort030211 gastroenterology & hepatology[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieNeoplasm Recurrence LocalbusinessDirect acting
researchProduct

Surveillance for hepatocellular carcinoma with a 3-months interval in “extremely high-risk” patients does not further improve survival

2022

Abstract Background An enhanced surveillance schedule has been proposed for cirrhotics with viral etiology, who are considered at extremely high-risk of hepatocellular carcinoma (HCC). Aims We compared the 3- and 6-months surveillance interval, evaluating cancer stage at diagnosis and patient survival. Methods Data of 777 HBV and HCV cirrhotic patients with HCC diagnosed under a 3-months (n = 109, 3MS group) or a 6-months (n = 668, 6MS group) surveillance were retrieved from the Italian Liver Cancer database. Survival in the 3MS group was considered as observed and adjusted for lead-time bias, and survival analysis was repeated after a propensity score matching. Results The 3-months surveil…

medicine.medical_specialtyCarcinoma HepatocellularSurvivalHepatocellular carcinomaCancer stageCancer stage; Hepatocellular carcinoma; Surveillance interval; SurvivalInternal medicinemedicineHumansPropensity ScoreSurveillance intervalSurvival analysisHigh risk patientsHepatologybusiness.industryCancer stageLiver NeoplasmsSettore MED/09 - MEDICINA INTERNAGastroenterologyPatient survivalmedicine.diseaseSurvival AnalysisHepatocellular carcinomaPropensity score matchingSurvival AnalysiLiver cancerbusinessMedian survivalHuman
researchProduct

Protective Role of Conization Before Radical Hysterectomy in Early-Stage Cervical Cancer: A Propensity-Score Matching Study.

2021

Purpose: The purpose of this study was to assess the prognostic role and the perioperative outcomes of conization performed before radical hysterectomy in early-stage cervical carcinoma. Methods: This multicenter, retrospective observational cohort study included patients with FIGO 2009 stage IB1 cervical carcinoma treated with radical hysterectomy between June 2004 and June 2019. Patients were divided into two groups according to conization before radical surgery. One-to-one case–control matching was used to adjust the baseline characteristics. Results: A total of 332 patients were included after propensity matching (166, 50% in each group). Twenty-four of 166 (14.4%) and 142 of 166 (85.6%…

medicine.medical_specialtyConizationUterine Cervical NeoplasmsHysterectomy03 medical and health sciences0302 clinical medicineMedicineHumansRisk factorStage (cooking)Radical surgeryRadical HysterectomyNeoplasm StagingRetrospective StudiesCervical cancerbusiness.industryPerioperativemedicine.diseaseSurgeryNeoplasm RecurrenceSettore MED/40 - GINECOLOGIA E OSTETRICIALocalOncology030220 oncology & carcinogenesisPropensity score matchingCervical cancer030211 gastroenterology & hepatologySurgeryFemaleNeoplasm Recurrence LocalbusinessCohort studyAnnals of surgical oncologyREFERENCES
researchProduct

Safety and efficacy of biodegradable polymer-coated thin strut sirolimus-eluting stent vs. durable polymer-coated everolimus-eluting stent in patient…

2018

Introduction The biodegradable polymer drug-eluting stents were developed to improve vascular healing. However, further data are needed to confirm the safety and efficacy of these stents in patients with acute myocardial infarction (AMI). Aim We sought to determine the 1-year clinical follow-up in patients with AMI treated with a thin strut biodegradable polymer-coated sirolimus-eluting stent (BP-SES) versus a durable coating everolimus-eluting stent (DP-EES). Material and methods We analyzed patients with AMI (STEMI and NSTEMI) treated with either a BP-SES (ALEX, Balton, Poland, n = 886) or DP-EES (XIENCE, Abbott, USA, n = 1054) with available 1-year clinical follow-up using propensity sco…

medicine.medical_specialtyEverolimus eluting stentmedicine.medical_treatmentacute myocardial infarctionlcsh:Medicine030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicinemedicineIn patientcardiovascular diseases030212 general & internal medicineMyocardial infarctionOriginal Paperbusiness.industrylcsh:Rdrug-eluting stentsStentPercutaneous coronary interventionequipment and suppliesmedicine.diseaseBiodegradable polymerSurgerybioabsorbable polymerSirolimusPropensity score matchingCardiology and Cardiovascular Medicinebusinessmedicine.drugAdvances in Interventional Cardiology
researchProduct

1-Year Outcomes of Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Stents

2016

Abstract Objectives The purpose of this study was to compare the 1-year outcomes of the ABSORB everolimus-eluting bioresorbable scaffold (BRS) (Abbott Vascular, Santa Clara, California) and the XIENCE everolimus-eluting stent (EES) (Abbott Vascular) in patients undergoing percutaneous coronary intervention. Background Randomized studies of the ABSORB BRS have been performed in selected patient and lesion scenarios. The available registries of the ABSORB BRS reflect real-world practice more closely compared with randomized studies, but most of them are limited by the small sample size and the lack of comparative outcomes versus second-generation drug-eluting stents. Methods A total of 1,189 …

medicine.medical_specialtyEverolimusbusiness.industrymedicine.medical_treatmentPercutaneous coronary interventionStent030204 cardiovascular system & hematologymedicine.diseaseConfidence interval03 medical and health sciences0302 clinical medicineInternal medicinePropensity score matchingConventional PCIClinical endpointmedicineCardiology030212 general & internal medicineMyocardial infarctionCardiology and Cardiovascular Medicinebusinessmedicine.drugJACC: Cardiovascular Interventions
researchProduct

Real-life impact of early interferonβ therapy in relapsing multiple sclerosis

2009

Objective: Recent findings support greater efficacy of early vs. delayed interferon beta (IFN) treatment in patients with a first clinical event suggestive of multiple sclerosis (MS). We aimed to evaluate the effectiveness of early IFN treatment in definite relapsing-remitting MS (RRMS) and to assess the optimal time to initiate IFN treatment with regard to the greatest benefits on disability progression. Methods: A cohort of 2,570 IFN-treated RRMS patients was prospectively followed for up to 7 years in 15 Italian MS Centers. A Cox proportional hazards regression model adjusted for propensity score (PS) quintiles was used to assess differences between groups of patients with early vs. dela…

medicine.medical_specialtyExpanded Disability Status Scalebusiness.industryMultiple sclerosisHazard ratiomedicine.diseaseSurgeryCentral nervous system diseaseNeurologyInternal medicinePropensity score matchingCohortmedicineObservational studyNeurology (clinical)Unmeasured confoundingbusinessAnnals of Neurology
researchProduct

Peginterferon-Α_2B plus ribavirin is more effective than peginterferon-Α_2A plus ribavirin in menopausal women with chronic hepatitis C

2012

Summary.  Under-enrolment of women to randomized clinical trials, including chronic hepatitis C, has long been recognized. The aim of this study was to identify factors predictive of sustained virological response (SVR) to PEG IFN/Ribavirin antiviral therapy in relation to gender and reproductive status of female patients involved. Seven hundred and forty-six treatment-naive patients (431 men, 315 women) treated with Peg-IFNα-2a (180 μg/week) or Peg-IFNα-2b (1.5 μg/kg/week) plus ribavirin (800–1400  mg/day) for 24 or 48 weeks were studied between 2006 and 2010. Differences in SVR rate, overall and by gender were assessed after adjustment and propensity score matching. SVR was obtained in 44…

medicine.medical_specialtyHepatitis C virusPopulationmacromolecular substancesmedicine.disease_causeGastroenterologylaw.inventionchemistry.chemical_compoundRandomized controlled triallawVirologyInternal medicineMedicineeducationeducation.field_of_studyHepatologybusiness.industryRibavirintechnology industry and agriculturevirus diseasesmedicine.diseasedigestive system diseasesMenopauseInfectious DiseasesEndocrinologychemistryPropensity score matchingSteatosisMetabolic syndromebusinessJournal of Viral Hepatitis
researchProduct

Perioperative chemotherapy versus surgery alone for resectable colorectal liver metastases: an international multicentre propensity score matched ana…

2021

Abstract Background There is still uncertainty regarding the role of perioperative chemotherapy (CTx) in patients with resectable colorectal liver metastases (CRLM), especially in those with a low-risk of recurrence. Methods Multicentre retrospective analysis of patients with CRLM undergoing liver resection between 2010–2015. Patients were divided into two groups according to whether they received perioperative CTx or not and were compared using propensity score matching (PSM) analysis. Then, they were stratified according to prognostic risk scores, including: Clinical Risk Score (CRS), Tumour Burden Score (TBS) and Genetic And Morphological Evaluation (GAME) score. Results The study includ…

medicine.medical_specialtyIndependent predictorResection03 medical and health sciences0302 clinical medicineRisk FactorsPerioperative chemotherapyLong term outcomesmedicineOverall survivalHepatectomyHumansPropensity ScoreRetrospective StudiesHepatologybusiness.industryLiver NeoplasmsGastroenterologyPerioperativePrognosisSurgery030220 oncology & carcinogenesisPropensity score matching030211 gastroenterology & hepatologyNeoplasm Recurrence LocalColorectal NeoplasmsbusinessClinical risk factorHPB
researchProduct

058 THE ROLE OF FEMALE SEX IN THE CONTEMPORARY TREATMENT OF THE LEFT MAIN CORONARY ARTERY INSIGHTS FROM THE W-DELTA (WOMEN-DRUG ELUTING STENT FOR LEF…

2013

Background The optimal revascularization strategy of women with unprotected left main coronary artery (ULMCA) disease is unknown. Therefore, the aim of this study was to evaluate long-term clinical outcomes in this cohort treated with percutaneous coronary intervention (PCI) utilising drug-eluting stents (DES) versus coronary artery bypass grafting (CABG). Methods All consecutive women from the Drug Eluting stent for LefT main coronary Artery disease (DELTA) Registry with ULMCA disease treated by PCI with DES or CABG were analysed. A propensity matching was performed to adjust for baseline differences between the 2 treatment groups. Results In total, 818 women were included: 489 (59.8%) und…

medicine.medical_specialtyInterventional cardiologybusiness.industrymedicine.medical_treatmentPercutaneous coronary interventionRevascularizationmedicine.diseaseDrug-eluting stentInternal medicineConventional PCIPropensity score matchingCardiologymedicinecardiovascular diseasesMyocardial infarctionCardiology and Cardiovascular MedicinebusinessStrokeHeart
researchProduct